KRYS
NASDAQ
$339.06
Krystal Biotech Inc (KRYS)
Krystal Biotech, Inc., a clinical-stage biotechnology company, is dedicated to the field of redosable gene therapy to treat serious rare diseases in the United States. The company is headquartered in Pittsburgh, Pennsylvania.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $361.67 (+6.67%)
Market Cap
$10B
PEG Ratio
0.57
Profit Margin
48.1%
P/E Ratio
45.34
Price Chart
Valuation
Market Cap$10B
P/E45.34
Forward P/E46.95
PEG0.57
P/S25.84
P/B8.45
Profitability
Total Revenue (TTM)$417M
Gross Profit (TTM)$393M
EBITDA$185M
Profit Margin48.1%
Operating Margin46.1%
EPS$7.72
Financial Health
Free Cash Flow Yield2.30%
Growth & Risk
Beta (5Y)0.92
Sharpe Ratio2.15